Table 1.
Descriptive Data for Our AML Patients
| Variable | No (%) |
|---|---|
| Sex | |
| Male | 18 (35 %) |
| Female | 34 (65 %) |
| Age | |
| Median (range) | 43 (19-70) |
| <50 years | 37 (71 %) |
| ≥50years | 15 (29 %) |
| TLCs (x 109/L) | |
| mean±SD | 49.6±87.2 |
| < 50 | 38/52* (73%) |
| ≥ 50 | 14/52 (27%) |
| HB (gm/dL) | |
| mean±SD | 7.8± 1.9 |
| < 8 | 30/52 (58%) |
| ≥ 8 | 22/52 (42%) |
| Platelets (x 109/L) | |
| mean±SD | 77.6± 141.5 |
| < 50 | 39/52 (75%) |
| ≥ 50 | 13/52 (25%) |
| Percent of Peripheral blood blasts | |
| mean±SD | 46.1 %±27.3 |
| < 50 | 23/52 (44%) |
| ≥ 50 | 29/52 (56%) |
| B.M cellularity | |
| Hypercellular | 39/52(75%) |
| Normocellular | 13/52(25%) |
| Percent of BM blasts | |
| mean±SD | 60.5 %± 23.1 |
| <50% | 14/52 (27%) |
| ≥50% | 38/52 (73%) |
| Immunophenotyping markers | |
| Myeloid | 34/52 (65.4%) |
| Myeloid with CD4 and CD14 | 11/52 (21%) |
| Myeloid with aberrant CD7 | 3/52 (5.8%) |
| Myeloid with aberrant CD19 | 2/52 (3.8%) |
| Myeloid with aberrant CD56 | 1/52 (1.9%) |
| Myeloid with CD61 | 1/52 (1.9%) |
| CD 34+ve | 32/52 (62%) |
| CD 34 –ve | 20/52 (38%) |
| Cytogenetics | |
| No mitosis | 10/39** (25.6%) |
| Normal karyotype | 9/29*** ( 31.1 % ) |
| t (9; 22) | 5/29 (17.2 %) |
| t (8;21) | 3/29 (10.3%) |
| t (15;17) | 4/29(13.8 %) |
| Complex karyotyping | 8/29 (27.6 %) |
*52 is the total number of AML cases; **39 is the total number of AML cases undergoing cytogenetic analysis; ***29 is the total number of AML cases undergoing cytogenetic analysis after exclusion of cases showing no mitosis.